Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Synerkine Pharma B.V.. (3/25/19). "Press Release: Synerkine Pharma Raises EUR3.3 Million in Series A Financing". Utrecht.

Organisations Organisation Synerkine Pharma B.V.
  Organisation 2 Thuja Capital B.V.
Products Product fusion protein
  Product 2 venture capital
Index term Index term Synerkine Pharma–SEVERAL: investment, 201903 financing round Series A €3.3m from Thuja Capital + private investor + company founders
Persons Person Preusting, Hans (Synerkine Pharma 2018– CEO + Co-Founder)
  Person 2 Herklots, Hans (LifeSci 201805 LifeSci Advisors before Carpicorn One + TiGenix)
     


Proceeds to build pipeline of novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain


Synerkine Pharma B.V., which develops fusion proteins for the treatment of chronic pain, announced today that it successfully closed a EUR 3.3 million Series A financing from Thuja Capital, an undisclosed private investor, and the company’s founders.

Hans Preusting, co-founder and CEO of Synerkine Pharma, said: “We are delighted with the closing of the Series A financing. The proceeds will allow us to deliver a pre-clinical proof of concept in osteoarthritis and neuropathic pain over the next two years. Our lead compound licensed from the University Medical Center Utrecht (UMCU), a fusion protein of IL4 and IL10, has been shown to significantly reduce chronic pain in multiple pre-clinical models. The therapeutic potential of fusion proteins that mimic endogenous immune molecules and are devoid of the typical analgesic side-effects is substantial in a broad range of pain indications.”


About Synerkine Pharma

Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. Synerkine Pharma was founded in 2018 and has licensed the exclusive rights of its lead compound, a fusion protein of IL4 and IL10, from the University Medical Center Utrecht (UMCU), the Netherlands. This fusion protein targets common regulatory mechanisms in different types of chronic pain, and has unique properties as demonstrated by UMCU researchers, who showed that it is effective in reducing pain in multiple pre-clinical models. The ability to treat pain with drugs that mimic endogenous immune molecules and are based on a different mechanism of action than the current anti-analgesic drugs holds tremendous therapeutic and commercial potential.


About Thuja Capital

Thuja Capital manages several healthcare venture capital funds that invest in private companies that aim to have a lasting impact on patients and society. Thuja typically invests in biotech, nutraceuticals, medtech, and digital health. The team of Thuja leverages its deep operational, strategic and investment experience to support its portfolio companies. For further information, visit thujacapital.com.


Contacts

Hans Preusting, PhD, MBA
Chief Executive Officer
+31 620 783 355
hans@synerkinepharma.com

Hans Herklots
Capricorn One
+41 79 598 7149
capricorn1@bluewin.ch

   
Record changed: 2019-03-31

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px




» top